KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Other Non-Current Liabilities (2020 - 2025)

Ginkgo Bioworks Holdings (DNA) has disclosed Other Non-Current Liabilities for 4 consecutive years, with $20.1 million as the latest value for Q2 2023.

  • For the quarter ending Q2 2023, Other Non-Current Liabilities changed N/A year-over-year to $20.1 million, compared with a TTM value of $20.1 million through Jun 2023, changed N/A, and an annual FY2022 reading of $10.9 million, down 69.8% over the prior year.
  • Other Non-Current Liabilities was $20.1 million for Q2 2023 at Ginkgo Bioworks Holdings, down from $29.3 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $212.9 million in Q3 2021 and bottomed at $3.0 million in Q4 2020.
  • Average Other Non-Current Liabilities over 4 years is $69.5 million, with a median of $34.9 million recorded in 2022.
  • The sharpest move saw Other Non-Current Liabilities surged 1087.07% in 2021, then plummeted 83.6% in 2022.
  • Year by year, Other Non-Current Liabilities stood at $3.0 million in 2020, then soared by 1087.07% to $36.0 million in 2021, then crashed by 69.8% to $10.9 million in 2022, then skyrocketed by 84.91% to $20.1 million in 2023.
  • Business Quant data shows Other Non-Current Liabilities for DNA at $20.1 million in Q2 2023, $29.3 million in Q1 2023, and $10.9 million in Q4 2022.